
Scientific Publications
Manuscripts
Evaluation of cost-effectiveness of adjuvant osimertinib in patients with resected EGFR mutation-positive non-small cell lung cancer
PharmacoEconomics - Open
Verhoek A et al
Case studies for overcoming challenges in using big data in cancer
Cancer Research
Sweeney SM et al
Incidence of SARS-CoV-2 and subsequent mortality in a multi-site cohort of patients with cancer in the CancerLinQ Discovery database
JCO Oncology Practice
Ray et al
Retrospective analysis of real‐world management of EGFR‐mutated advanced NSCLC, after first‐line EGFR‐TKI treatment: US treatment patterns, attrition,…
Drugs Real World Outcomes
Nieva J et al
Reaching beyond maximum grade: Progress and future directions for modernising the assessment and reporting of adverse events in haematological maligna…
The Lancet Haematology
Thanarajasingam G et al.
Cancer registry data linkage of electronic health record data from ASCO’s CancerLinQ: Evaluation of advantages, limitations, and lessons learned
JCO Clinical Cancer Informatics
Charlton et al.
Real-world clinical outcomes of patients with BRCA-mutated, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer: a Cance…
Breast Cancer Research and Treatment
Miller et al.
Quantitating and Assessing Interoperability Between Electronic Health Records
Journal of the American Medical Informatics Association
Bernstam et al.
Abstracts
Real-world treatment patterns and sequencing in patients with locally advanced or metastatic urothelial cancer in the US
2023 ASCO Genitourinary Cancers Symposium
Kearney M
Survival of patients with multiple myeloma diagnosed with second primary malignancies: An ASCO CancerLinQ analysis
2022 ASH Annual Meeting
Cooper JD
Secondary primary malignancies in adolescent and young adults with multiple myeloma: An ASCO CancerLinQ analysis
2022 ASH Annual Meeting
Gibson SJ
Racial disparities in newly diagnosed hematological malignancies in the United States during the COVID-19 pandemic, January 2020 to March 2021
2022 ASH Annual Meeting
Bhandari S
Real world treatment patterns of adjuvant endocrine therapy and ovarian suppression in premenopausal HR+/HER2+ breast cancer
2022 San Antonio Breast Cancer Symposium
Sukumar JS
Demographics, clinical characteristics, treatment patterns and clinical outcomes of patients with stages I-III resected NSCLC without known EGFR mutat…
2022 ESMO Congress
Altorki NK
Long term survival outcomes in NSCLC patients with targeted therapy and immunotherapy: An IASLC analysis of ASCO CancerLinQ Discovery data
2022 World Conference on Lung Cancer
Behera M et al
Disparities in timely treatment among lung cancer patients
ASCO 2022 Annual Meeting
Chhabra J
Diagnosed with advanced prostate cancer: A population-based cohort from national oncology practices
ASCO 2022 Annual Meeting
Kim SP